Zobrazeno 1 - 10
of 242
pro vyhledávání: ''
Autor:
Mark A. Schroeder, Steven M. Devine, Yi-Bin Chen, Andrejus Parfionovas, Yngvar Fløisand, Syed Quadri, Dominik Selleslag, Chunlin Chen, Ibrahim Yakoub-Agha, Patrice Chevallier, Mona Akbari, Mohamad Mohty, Johan Jansson, Anne S. Renteria
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, In press, ⟨10.1038/s41409-021-01356-0⟩
Bone Marrow Transplantation, Nature Publishing Group, In press, ⟨10.1038/s41409-021-01356-0⟩
Bone Marrow Transplantation, In press, ⟨10.1038/s41409-021-01356-0⟩
Bone Marrow Transplantation, Nature Publishing Group, In press, ⟨10.1038/s41409-021-01356-0⟩
Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there are n
Publikováno v:
Bone Marrow Transplantation
Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic stem cell transplant (HSCT) with high morbidity and mortality. The triad of endothelial cell activation, complement dysregulation, a
Autor:
Stéphanie Bolle, Cristina Veres, Nadia Haddy, Amel Belhout, Giao Vu-Bezin, Brice Fresneau, Sophie Rivollet, Vincent Souchard, Florent de Vathaire, Neige Journy, Sandrine Haghiri, Christelle Dufour, Chiraz Fayech, Amel Boumaraf, Dominique Valteau-Couanet, Agnès Dumas, Imene Mansouri, Claudia Pasqualini
Publikováno v:
Bone Marrow Transplantation. 56:1984-1997
Intensive treatments including high-dose chemotherapy (HDC) with autologous stem cell rescue have improved high-risk neuroblastoma (HRNB) survival. We report the long-term health status of 145 HRNB survivors, alive and disease-free 5 years post HDC.
Autor:
Claude Eric Bulabois, Nicole Raus, Anne Huynh, Valerie Rolland, Marie Hélène Schlageter, Brigitte Dupriez, Jean-Jacques Kiladjian, Edouard Forcade, David Michonneau, Stéphanie N. Guyen, Alban Villate, Fiorenza Barraco, Raphaël Porcher, Felipe Suarez, Bruno Cassinat, Amandine Charbonnier, Françoise Boyer, Jacques-Olivier Bay, Gérard Socié, Jérôme Cornillon, Sylvain Chantepie, Ibrahim Yakoub-Agha, Laure Vincent, Pascal Turlure, Marie Robin, Corentin Orvain, Marie Y Detrait
Publikováno v:
Bone Marrow Transplantation
This multicenter prospective phase 2 trial analyzed disease-free survival (DFS) in myelofibrosis patients receiving ruxolitinib for 6 months before transplantation. Seventy-six patients were recruited. Age-adjusted dynamic international prognostic sc
Autor:
Ravi Shah
Publikováno v:
Bone Marrow Transplantation. 56:1518-1534
The barriers to HLA-mismatched or haploidentical hematopoietic stem cell transplantation (HSCT), namely GvHD and graft failure, have been overcome with novel transplant platforms. Post-transplant Cyclophosphamide (PTCy) is widely available, feasible
Autor:
Xiaoxuan Lai, Gaohui Yang, Lingling Shi, Zhongming Zhang, Qiaochuan Li, Yongrong Lai, Rongrong Liu, Rui Huang, Lianjin Liu, Meiqing Wu
Publikováno v:
Bone Marrow Transplantation
Hepatic veno-occlusive disease or sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the present prospective study, we aimed to investigate th
Autor:
Ruth Pettengell, Ariane Boumendil, Joanna Romejko-Jarosinska, R Johnson, Peter Dreger, Stephen P. Robinson, Alejandro Martín, Eva Kimby, N. Schmitz, P Giri, Carsten Utoft Niemann, Anthony H. Goldstone, Isabelle Bence-Bruckler, Bernd Metzner, Silvia Montoto, Ruzena Uddin
Publikováno v:
Bone Marrow Transplantation. 56:1413-1421
We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to determine whether the benefit of brief duration rituximab maintenance (RM) on progression-free survival (PFS) in patients with relapsed follicular lymphoma (FL) receivin
Autor:
Xiao-Jun Huang, Zheng-Li Xu
Publikováno v:
Bone Marrow Transplantation. 56:779-785
Haematopoietic stem cell transplantation (HSCT) is a curative option for severe aplastic anemia (SAA). Finding a suitable matched donor in a timely manner is a challenge. The availability of haploidentical donors and their successful use in transplan
Autor:
Ernst Holler, Panagiotis Tsirigotis, Gloria Tridello, Andreas H. Groll, Emmanouil Nikolousis, Carlos Solano, Lotus Wendel, Franca Fagioli, Per Ljungman, Nicole M. A. Blijlevens, Bruno Lioure, Lidia Gil, Nina Knelange, Jiří Šrámek, Christian Junghanss, Stephan Mielke, Malgorzata Mikulska, Michael Medinger, Jan Styczyński, Federica Galaverna, Rafael de la Cámara, Aliénor Xhaard, Mervi Taskinen, Alessandra Biffi, M. Aranzazu Bermudez Rodriguez
Publikováno v:
Bone Marrow Transplantation, 56, 5, pp. 1171-1179
BONE MARROW TRANSPLANTATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Bone Marrow Transplantation, 56, 1171-1179
BONE MARROW TRANSPLANTATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Bone Marrow Transplantation, 56, 1171-1179
Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the app
Autor:
Sonja Genadieva Stavrik, Sascha Dietricht, Norbert Schmitz, Stephen D. Robinson, Peter Dreger, Anna Sureda, Alina Tanase, Irma Khvedelidze, Herve Finel, Olivier Hermine, Chara Kyriakou, Harry C. Schouten, Silvia Montoto, Ariane Boumendil
Publikováno v:
Bone Marrow Transplantation, 55(11), 2170-2179. Nature Publishing Group
Indications for autologous (auto-HCT) and allogeneic transplantation (allo-HCT) in relapsed/refractory Hodgkin lymphoma (rrHL) have been long established. The expectation is that long-term outcomes have significantly improved over time with increased